The multifaceted functions of mineralocorticoid receptor in cardiometabolic disease

¹ Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China

² National Centre for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai 200011, China

³ Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China

Global Translational Medicine 2023, 2(1), 229 https://doi.org/10.36922/gtm.v2i1.229

Submitted: 19 October 2022 | Accepted: 24 November 2022 | Published: 12 January 2023

© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Cardiometabolic diseases (CMDs), which cause 31% of all global deaths, are one of the greatest public health challenges. Mineralocorticoid receptor (MR), as a key nuclear transcription factor, is an important drug target for the treatment of CMDs. It is known that MR is expressed in almost all tissues and organs involved in cardiovascular homeostasis, including immune tissue, adipose tissue, brain, heart, kidney, and blood vessels. In the pathophysiology of CMDs, MR exerts different functions in different tissues and cells. This review summarizes the roles of MR in various cell types and discusses the molecular mechanisms through which MR exerts it functions in CMDs.

Keywords

Cardiometabolic diseases

Mineralocorticoid receptor

Mineralocorticoid receptor antagonist

Funding

National Natural Science Foundation of China

Innovative Research Team of High-Level Local Universities in Shanghai

Conflict of interest

The authors declare that they have no competing interest.

References

[1]

Arnett DK, Blumenthal RS, Albert MA, et al., 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 140: e596–e646. https://doi.org/10.1161/CIR.0000000000000678

[2]

Sattar N, Gill JM, Alazawi W, 2020, Improving prevention strategies for cardiometabolic disease. Nat Med, 26: 320–325. https://doi.org/10.1038/s41591-020-0786-7

[3]

Bluher M, 2019, Obesity: Global epidemiology and pathogenesis. Nat Rev Endocrinol, 15: 288–298. https://doi.org/10.1038/s41574-019-0176-8

[4]

Joseph P, Leong D, McKee M, et al., 2017, Reducing the global burden of cardiovascular disease, Part 1: The epidemiology and risk factors. Circ Res, 121: 677–694. https://doi.org/10.1161/circresaha.117.308903

[5]

Barrera-Chimal J, Lima-Posada I, Bakris GL, et al., 2022, Mineralocorticoid receptor antagonists in diabetic kidney disease-mechanistic and therapeutic effects. Nat Rev Nephrol, 18: 56–70. https://doi.org/10.1038/s41581-021-00490-8

[6]

Belden Z, Deiuliis JA, Dobre M, et al., 2017, The role of the mineralocorticoid receptor in inflammation: Focus on kidney and vasculature. Am J Nephrol, 46: 298–314. https://doi.org/10.1159/000480652

[7]

Buonafine M, Bonnard B, Jaisser F, 2018, Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens, 31: 1165–1174. https://doi.org/10.1093/ajh/hpy120

[8]

Rossier BC, 2002, Hormonal regulation of the epithelial sodium channel enac: N or P(o)? J Gen Physiol, 120: 67–70. https://doi.org/10.1085/jgp.20028638

[9]

Rossier BC, Staub O, Hummler E, 2013, Genetic dissection of sodium and potassium transport along the aldosterone-sensitive distal nephron: Importance in the control of blood pressure and hypertension. FEBS Lett, 587: 1929–1941. https://doi.org/10.1016/j.febslet.2013.05.013

[10]

Ivanes F, Susen S, Mouquet F, et al., 2012, Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J, 33: 191–202. https://doi.org/10.1093/eurheartj/ehr176

[11]

Milliez P, Girerd X, Plouin PF, et al., 2005, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 45: 1243–1248. https://doi.org/10.1016/j.jacc.2005.01.015

[12]

Funder JW, 2004, Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol, 217: 263–269. https://doi.org/10.1016/j.mce.2003.10.054

[13]

Brown NJ, 2008, Aldosterone and vascular inflammation. Hypertension, 51: 161–167. https://doi.org/10.1161/hypertensionaha.107.095489

[14]

Arriza JL, Weinberger C, Cerelli G, et al., 1987, Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science, 237: 268–275. https://doi.org/10.1126/science.3037703

[15]

Barrera-Chimal J, Jaisser F, 2019, Vascular mineralocorticoid receptor activation and disease. Exp Eye Res, 188: 107796. https://doi.org/10.1016/j.exer.2019.107796

[16]

Shibata S, Nagase M, Yoshida S, et al., 2008, Modification of mineralocorticoid receptor function by Rac1 GTpase: Implication in proteinuric kidney disease. Nat Med, 14: 1370–1376.https://doi.org/10.1038/nm.1879

[17]

Nagase M, Fujita T, 2013, Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol, 9: 86–98. https://doi.org/10.1038/nrneph.2012.282

[18]

Hayashi T, Shibata H, Kurihara I, et al., 2017, High glucose stimulates mineralocorticoid receptor transcriptional activity through the protein kinase C β signaling. Int Heart J, 58: 794–802. https://doi.org/10.1536/ihj.16-649

[19]

Nagase M, Matsui H, Shibata S, et al., 2007, Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: Role of oxidative stress. Hypertension, 50: 877–883. https://doi.org/10.1161/hypertensionaha.107.091058

[20]

Cole TJ, Young MJ, 2017, 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor null mice: Informing cell-type-specific roles. J Endocrinol, 234: T83–T92. https://doi.org/10.1530/joe-17-0155

[21]

Kolkhof P, Joseph A, Kintscher U, 2021, Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders-new perspectives for combination therapy. Pharmacol Res, 172: 105859. https://doi.org/10.1016/j.phrs.2021.105859

[22]

Usher MG, Duan SZ, Ivaschenko CY, et al., 2010, Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest, 120: 3350–3364. https://doi.org/10.1172/jci41080

[23]

Sun JY, Li C, Shen ZX, et al., 2016, Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1/NF-κBpathways. Arterioscler Thromb Vasc Biol, 36: 874–885. https://doi.org/10.1161/atvbaha.115.307031

[24]

McCurley A, Pires PW, Bender SB, et al., 2012, Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med, 18: 1429–1433. https://doi.org/10.1038/nm.2891

[25]

Nguyen Dinh A, Griol-Charhbili V, Loufrani L, et al., 2010, The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J, 24: 2454–2463. https://doi.org/10.1096/fj.09-147926

[26]

Mueller KB, Bender SB, Hong K, et al., 2015, Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension, 66: 988–997. https://doi.org/10.1161/hypertensionaha.115.06172

[27]

Sun XN, Li C, Liu Y, et al., 2017, T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. Circ Res, 120: 1584–1597. https://doi.org/10.1161/circresaha.116.310480

[28]

Wu H, Ballantyne CM, 2020, Metabolic inflammation and insulin resistance in obesity. Circ Res, 126: 1549–1564. https://doi.org/10.1161/circresaha.119.315896

[29]

Ferreira NS, Tostes RC, Paradis P, et al., 2021, Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens, 34: 15–27. https://doi.org/10.1093/ajh/hpaa137

[30]

Van der Heijden C, Bode M, Riksen NP, et al., 2022, The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. Br J Pharmacol, 179: 3135–3151. https://doi.org/10.1111/bph.15782

[31]

Moore KJ, Tabas I, 2011, Macrophages in the pathogenesis of atherosclerosis. Cell, 145: 341–355. https://doi.org/10.1016/j.cell.2011.04.005

[32]

Keidar S, Kaplan M, Pavlotzky E, et al., 2004, Aldosterone administration to mice stimulates macrophage nadph oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation, 109: 2213–2220. https://doi.org/10.1161/01.cir.0000127949.05756.9D

[33]

Keidar S, Hayek T, Kaplan M, et al., 2003, Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 41: 955–963. https://doi.org/10.1097/00005344-200306000-00019

[34]

Shen ZX, Chen XQ, Sun XN, et al., 2017, Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis. J Biol Chem, 292: 925–935. https://doi.org/10.1074/jbc.M116.739243

[35]

Man JJ, Lu Q, Moss ME, et al., 2021, Myeloid mineralocorticoid receptor transcriptionally regulates p-selectin glycoprotein ligand-1 and promotes monocyte trafficking and atherosclerosis. Arterioscler Thromb Vasc Biol, 41: 2740–2755. https://doi.org/10.1161/atvbaha.121.316929

[36]

Fraccarollo D, Thomas S, Scholz CJ, et al., 2019, Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing. Hypertension, 73: 102–111. https://doi.org/10.1161/hypertensionaha.118.12162

[37]

Rickard AJ, Morgan J, Tesch G, et al., 2009, Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension, 54: 537–543. https://doi.org/10.1161/hypertensionaha.109.131110

[38]

Bienvenu LA, Morgan J, Rickard AJ, et al., 2012, Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology, 153: 3416–3425. https://doi.org/10.1210/en.2011-2098

[39]

Olefsky JM, Glass CK, 2010, Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 72: 219–246. https://doi.org/10.1146/annurev-physiol-021909-135846

[40]

Guo C, Ricchiuti V, Lian BQ, et al., 2008, Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation, 117: 2253–2261. https://doi.org/10.1161/circulationaha.107.748640

[41]

Wada T, Kenmochi H, Miyashita Y, et al., 2010, Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology, 151: 2040–2049. https://doi.org/10.1210/en.2009-0869

[42]

Zhang YY, Li C, Yao GF, et al., 2017, Deletion of macrophage mineralocorticoid receptor protects hepatic steatosis and insulin resistance through ERα/HGF/Met pathway. Diabetes, 66: 1535–1547. https://doi.org/10.2337/db16-1354

[43]

Vinh A, Chen W, Blinder Y, et al., 2010, Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation, 122: 2529–2537. https://doi.org/10.1161/circulationaha.109.930446

[44]

Hevia D, Araos P, Prado C, et al., 2018, Myeloid CD11c+ antigen-presenting cells ablation prevents hypertension in response to angiotensin II plus high-salt diet. Hypertension, 71: 709–718. https://doi.org/10.1161/hypertensionaha.117.10145

[45]

Hengel FE, Benitah JP, Wenzel UO, 2022, Mosaic theory revised: Inflammation and salt play central roles in arterial hypertension. Cell Mol Immunol, 19: 561–576. https://doi.org/10.1038/s41423-022-00851-8

[46]

Herrada AA, Contreras FJ, Marini NP, et al., 2010, Aldosterone promotes autoimmune damage by enhancing TH17-mediated immunity. J Immunol, 184: 191–202. https://doi.org/10.4049/jimmunol.0802886

[47]

Amador CA, Barrientos V, Pena J, et al., 2014, Spironolactone decreases doca-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension, 63: 797–803. https://doi.org/10.1161/hypertensionaha.113.02883

[48]

Bene NC, Alcaide P, Wortis HH, et al., 2014, Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease. Steroids, 91: 38–45. https://doi.org/10.1016/j.steroids.2014.04.005

[49]

Kirabo A, Fontana V, de Faria AP, et al., 2014, DC isoketal-modified proteins activate t cells and promote hypertension. J Clin Invest, 124: 4642–4656. https://doi.org/10.1172/JCI74084

[50]

Araos P, Prado C, Lozano M, et al., 2019, Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation. J Hypertens, 37: 1482–1492. https://doi.org/10.1097/HJH.0000000000002067

[51]

Buonafine M, Martinez-Martinez E, Amador C, et al., 2018, Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol, 115: 32–38. https://doi.org/10.1016/j.yjmcc.2017.12.011

[52]

Latouche C, El Moghrabi S, Messaoudi S, et al., 2012, Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension, 59: 966–972. https://doi.org/10.1161/hypertensionaha.111.187872

[53]

Guzik TJ, Hoch NE, Brown KA, et al., 2007, Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med, 204: 2449–2460. https://doi.org/10.1084/jem.20070657

[54]

Itani HA, McMaster WG Jr., Saleh MA, et al., 2016, Activation of human T cells in hypertension: Studies of humanized mice and hypertensive humans. Hypertension, 68: 123–132. https://doi.org/10.1161/hypertensionaha.116.07237

[55]

Shen JZ, Young MJ, 2012, Corticosteroids, heart failure, and hypertension: A role for immune cells? Endocrinology, 153: 5692–5700. https://doi.org/10.1210/en.2012-1780

[56]

Chu PY, Zatta A, Kiriazis H, et al., 2011, CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail, 4: 651–658. https://doi.org/10.1161/circheartfailure.110.960831

[57]

Li C, Sun XN, Zeng MR, et al., 2017, Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension, 70: 137–147. https://doi.org/10.1161/hypertensionaha.117.09070

[58]

Adamo L, Rocha-Resende C, Mann DL, 2020, The emerging role of B lymphocytes in cardiovascular disease. Annu Rev Immunol, 38: 99–121. https://doi.org/10.1146/annurev-immunol-042617-053104

[59]

McLaughlin T, Ackerman SE, Shen L, et al., 2017, Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest, 127: 5–13. https://doi.org/10.1172/JCI88876

[60]

Soehnlein O, Libby P, 2021, Targeting inflammation in atherosclerosis-from experimental insights to the clinic. Nat Rev Drug Discov, 20: 589–610. https://doi.org/10.1038/s41573-021-00198-1

[61]

Pober JS, Sessa WC, 2007, Evolving functions of endothelial cells in inflammation. Nat Rev Immunol, 7: 803–815. https://doi.org/10.1038/nri2171

[62]

Poston RN, Haskard DO, Coucher JR, et al., 1992, Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol, 140: 665–673.

[63]

Iiyama K, Hajra L, Iiyama M, et al., 1999, Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res, 85: 199–207. https://doi.org/10.1161/01.res.85.2.199

[64]

Caprio M, Newfell BG, la Sala A, et al., 2008, Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res, 102: 1359–1367. https://doi.org/10.1161/circresaha.108.174235

[65]

Marzolla V, Armani A, Mammi C, et al., 2017, Essential role of icam-1 in aldosterone-induced atherosclerosis. Int J Cardiol, 232: 233–242. https://doi.org/10.1016/j.ijcard.2017.01.013

[66]

Moss ME, Lu Q, Iyer SL, et al., 2019, Endothelial mineralocorticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner. Arterioscler Thromb Vasc Biol, 39: 1588–1601. https://doi.org/10.1161/atvbaha.119.312954

[67]

Lother A, Furst D, Bergemann S, et al., 2016, Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension, 67: 130–138. https://doi.org/10.1161/hypertensionaha.115.06530

[68]

Rickard AJ, Morgan J, Chrissobolis S, et al., 2014, Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension, 63: 1033–1040. https://doi.org/10.1161/hypertensionaha.113.01803

[69]

Laursen SB, Finsen S, Marcussen N, et al., 2018, Endothelial mineralocorticoid receptor ablation does not alter blood pressure, kidney function or renal vessel contractility. PloS One, 13: e0193032. https://doi.org/10.1371/journal.pone.0193032

[70]

Zheng XJ, Liu Y, Zhang WC, et al., 2019, Mineralocorticoid receptor negatively regulates angiogenesis through repression of STAT3 activity in endothelial cells. J Pathol, 248: 438–451. https://doi.org/10.1002/path.5269

[71]

Kobayashi N, Fukushima H, Takeshima H, et al., 2010, Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am J Hypertens, 23: 1007–1013. https://doi.org/10.1038/ajh.2010.91

[72]

Zhao M, Mantel I, Gelize E, et al., 2019, Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nat Commun, 10: 369. https://doi.org/10.1038/s41467-018-08125-6

[73]

Hwang MH, Yoo JK, Luttrell M, et al., 2013, Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond), 125: 513–520. https://doi.org/10.1042/CS20130200

[74]

Schafer N, Lohmann C, Winnik S, et al., 2013, Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J, 34: 3515–3524. https://doi.org/10.1093/eurheartj/eht095

[75]

Jia G, Habibi J, DeMarco VG, et al., 2015, Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension, 66: 1159–1167. https://doi.org/10.1161/hypertensionaha.115.06015

[76]

Jia G, Habibi J, Aroor AR, et al., 2016, Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circ Res, 118: 935–943. https://doi.org/10.1161/circresaha.115.308269

[77]

Hassoun PM, 2021, Pulmonary arterial hypertension. N Engl J Med, 385: 2361–2376. https://doi.org/10.1056/NEJMra2000348

[78]

Maron BA, Leopold JA, 2015, Emerging concepts in the molecular basis of pulmonary arterial hypertension: Part II: Neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation, 131: 2079–2091. https://doi.org/10.1161/circulationaha.114.006980

[79]

Omidkhoda N, Vakilian F, Mohammadpour AH, et al., 2020, Aldosterone and mineralocorticoid receptor antagonists on pulmonary hypertension and right ventricular failure: A review. Curr Pharm Des, 26: 3862–3870. https://doi.org/10.2174/1381612826666200523171137

[80]

Maron BA, Opotowsky AR, Landzberg MJ, et al., 2013, Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: A pilot study. Eur J Heart Fail, 15: 277–283. https://doi.org/10.1093/eurjhf/hfs173

[81]

Calvier L, Legchenko E, Grimm L, et al., 2016, Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart, 102: 390–396. https://doi.org/10.1136/heartjnl-2015-308365

[82]

Preston IR, Sagliani KD, Warburton RR, et al., 2013, Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 304: L678–L688. https://doi.org/10.1152/ajplung.00300.2012

[83]

Boehm M, Arnold N, Braithwaite A, et al., 2018, Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulm Med, 18: 41. https://doi.org/10.1186/s12890-018-0604-x

[84]

Kowalski J, Deng L, Suennen C, et al., 2021, Eplerenone improves pulmonary vascular remodeling and hypertension by inhibition of the mineralocorticoid receptor in endothelial cells. Hypertension, 78: 456–465. https://doi.org/10.1161/hypertensionaha.120.16196

[85]

Lacolley P, Regnault V, Nicoletti A, et al., 2012, The vascular smooth muscle cell in arterial pathology: A cell that can take on multiple roles. Cardiovasc Res, 95: 194–204. https://doi.org/10.1093/cvr/cvs135

[86]

Galmiche G, Pizard A, Gueret A, et al., 2014, Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension, 63: 520–526. https://doi.org/10.1161/hypertensionaha.113.01967

[87]

DuPont JJ, McCurley A, Davel AP, et al., 2016, Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging. JCI Insight, 1: e88942. https://doi.org/10.1172/jci.insight.88942

[88]

Lu Q, Davel AP, McGraw AP, et al., 2019, PKCδ mediates mineralocorticoid receptor activation by angiotensin II to modulate smooth muscle cell function. Endocrinology, 160: 2101–2114. https://doi.org/10.1210/en.2019-00258

[89]

Gueret A, Harouki N, Favre J, et al., 2016, Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension, 67: 717–723. https://doi.org/10.1161/hypertensionaha.115.06709

[90]

Kim SK, Biwer LA, Moss ME, et al., 2021, Mineralocorticoid receptor in smooth muscle contributes to pressure overload-induced heart failure. Circ Heart Fail, 14: e007279. https://doi.org/10.1161/circheartfailure.120.007279

[91]

Gourdie RG, Dimmeler S, Kohl P, 2016, Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat Rev Drug Discov, 15: 620–638. https://doi.org/10.1038/nrd.2016.89

[92]

Barrera-Chimal J, Girerd S, Jaisser F, 2019, Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis. Kidney Int, 96: 302–319. https://doi.org/10.1016/j.kint.2019.02.030

[93]

Stockand JD, Meszaros JG, 2003, Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol, 284: H176–H184. https://doi.org/10.1152/ajpheart.00421.2002

[94]

Wang Q, Cui W, Zhang HL, et al., 2013, Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway. J Cardiovasc Pharmacol, 61: 520–527. https://doi.org/10.1097/FJC.0b013e31828c090e

[95]

Fullerton MJ, Funder JW, 1994, Aldosterone and cardiac fibrosis: In vitro studies. Cardiovasc Res, 28: 1863–1867. https://doi.org/10.1093/cvr/28.12.1863

[96]

Brilla CG, Zhou G, Matsubara L, et al., 1994, Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol, 26: 809–820. https://doi.org/10.1006/jmcc.1994.1098

[97]

Lother A, Berger S, Gilsbach R, et al., 2011, Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension, 57: 746–754. https://doi.org/10.1161/hypertensionaha.110.163287

[98]

Fraccarollo D, Bauersachs J, 2011, Cardiomyocyte mineralocorticoid receptor function post myocardial infarction. Trends Cardiovasc Med, 21: 42–47. https://doi.org/10.1016/j.tcm.2012.02.003

[99]

Fraccarollo D, Berger S, Galuppo P, et al., 2011, Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation, 123: 400–408. https://doi.org/10.1161/circulationaha.110.983023

[100]

Bienvenu LA, Reichelt ME, Morgan J, et al., 2015, Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult. Hypertension, 66: 970–977. https://doi.org/10.1161/hypertensionaha.115.05981

[101]

He BJ, Joiner ML, Singh MV, et al., 2011, Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med, 17: 1610–1618. https://doi.org/10.1038/nm.2506

[102]

Ayoub IM, Kolarova J, Yi Z, et al., 2003, Sodium-hydrogen exchange inhibition during ventricular fibrillation: Beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitability. Circulation, 107: 1804–1809. https://doi.org/10.1161/01.cir.0000058704.45646.0D

[103]

Rickard AJ, Morgan J, Bienvenu LA, et al., 2012, Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension, 60: 1443–1450. https://doi.org/10.1161/hypertensionaha.112.203158

[104]

Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al., 2005 Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation, 111: 3025–3033. https://doi.org/10.1161/circulationaha.104.503706

[105]

Lother A, Bergemann S, Kowalski J, et al., 2018, Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Cardiovasc Res, 114: 282–290. https://doi.org/10.1093/cvr/cvx078

[106]

Armani A, Marzolla V, Fabbri A, et al., 2015, Cellular mechanisms of mr regulation of adipose tissue physiology and pathophysiology. J Mol Endocrinol, 55: R1–R10. https://doi.org/10.1530/jme-15-0122

[107]

Caprio M, Feve B, Claes A, et al., 2007, Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J, 21: 2185–2194. https://doi.org/10.1096/fj.06-7970com

[108]

Hoppmann J, Perwitz N, Meier B, et al., 2010, The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol, 204: 153–164. https://doi.org/10.1677/JOE-09-0292

[109]

Caprio M, Antelmi A, Chetrite G, et al., 2011, Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome. Endocrinology, 152: 113–125. https://doi.org/10.1210/en.2010-0674

[110]

Lee MJ, Fried SK, 2014, The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. Int J Obes (Lond), 38: 1228–1233. https://doi.org/10.1038/ijo.2014.6

[111]

Hirata A, Maeda N, Hiuge A, et al., 2009, Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res, 84: 164–172. https://doi.org/10.1093/cvr/cvp191

[112]

Urbanet R, Nguyen Dinh Cat A, Feraco A, et al., 2015, Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension, 66: 149–157. https://doi.org/10.1161/hypertensionaha.114.04981

[113]

Armani A, Cinti F, Marzolla V, et al., 2014, Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J, 28: 3745–3757. https://doi.org/10.1096/fj.13-245415

[114]

Wada T, Ishikawa A, Watanabe E, et al., 2017, Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. J Endocrinol, 235: 179–191. https://doi.org/10.1530/joe-17-0351

[115]

Lefranc C, Friederich-Persson M, Braud L, et al., 2019, Mr (mineralocorticoid receptor) induces adipose tissue senescence and mitochondrial dysfunction leading to vascular dysfunction in obesity. Hypertension, 73: 458–468. https://doi.org/10.1161/hypertensionaha.118.11873

[116]

Nguyen Dinh Cat A, Antunes TT, Callera GE, et al., 2016, Adipocyte-specific mineralocorticoid receptor overexpression in mice is associated with metabolic syndrome and vascular dysfunction: Role of redox-sensitive PKG-1 and Rho kinase. Diabetes, 65: 2392–2403. https://doi.org/10.2337/db15-1627

[117]

Johansen ML, Ibarrola J, Fernandez-Celis A, et al., 2021, The mineralocorticoid receptor antagonist eplerenone suppresses interstitial fibrosis in subcutaneous adipose tissue in patients with Type 2 diabetes. Diabetes, 70: 196–203. https://doi.org/10.2337/db20-0394

[118]

Habibi J, Chen D, Hulse JL, et al., 2022, Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. Am J Physiol Regul Integr Comp Physiol, 322: R253–R262. https://doi.org/10.1152/ajpregu.00316.2021

[119]

Ferguson D, Hutson I, Tycksen E, et al., 2020, Role of mineralocorticoid receptor in adipogenesis and obesity in male mice. Endocrinology, 161: bqz010. https://doi.org/10.1210/endocr/bqz010

[120]

Lefranc C, Friederich-Persson M, Foufelle F, et al., 2021, Adipocyte-mineralocorticoid receptor alters mitochondrial quality control leading to mitochondrial dysfunction and senescence of visceral adipose tissue. Int J Mol Sci, 22: 2881. https://doi.org/10.3390/ijms22062881

[121]

Feraco A, Armani A, Urbanet R, et al., 2018, Minor role of mature adipocyte mineralocorticoid receptor in high fat induced obesity. J Endocrinol, 239: 229-240. https://doi.org/10.1530/joe-18-0314

[122]

Hayakawa T, Minemura T, Onodera T, et al., 2018, Impact of MR on mature adipocytes in high-fat/high-sucrose diet-induced obesity. J Endocrinol, 239: 63–71. https://doi.org/10.1530/joe-18-0026

[123]

Kuhn E, Bourgeois C, Keo V, et al., 2014, Paradoxical resistance to high-fat diet-induced obesity and altered macrophage polarization in mineralocorticoid receptor-overexpressing mice. Am J Physiol Endocrinol Metab, 306: E75–E90. https://doi.org/10.1152/ajpendo.00323.2013

[124]

Viengchareun S, Penfornis P, Zennaro MC, et al., 2001, Mineralocorticoid and glucocorticoid receptors inhibit ucp expression and function in brown adipocytes. Am J Physiol Endocrinol Metab, 280: E640–E649. https://doi.org/10.1152/ajpendo.2001.280.4.E640

[125]

Kuhn E, Lamribet K, Viengchareun S, et al., 2019, Ucp1 transrepression in brown fat in vivo and mineralocorticoid receptor anti-thermogenic effects. Ann Endocrinol (Paris), 80: 1–9. https://doi.org/10.1016/j.ando.2018.04.018

[126]

Marzolla V, Feraco A, Gorini S, et al., 2020, The novel non-steroidal mr antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via ampk-atgl pathway. FASEB J, 34: 12450–12465. https://doi.org/10.1096/fj.202000164R

[127]

Marzolla V, Feraco A, Limana F, et al., 2022, Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest, 45: 215–220. https://doi.org/10.1007/s40618-021-01635-z

[128]

Thuzar M, Law WP, Dimeski G, et al., 2019, Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study. Diabetes Obes Metab, 21: 509–516. https://doi.org/10.1111/dom.13539

[129]

Dirckx N, Morer MC, Clemens TL, et al., 2019, The role of osteoblasts in energy homeostasis. Nat Rev Endocrinol, 15: 651–665. https://doi.org/10.1038/s41574-019-0246-y

[130]

Lee NK, Sowa H, Hinoi E, et al., 2007, Endocrine regulation of energy metabolism by the skeleton. Cell, 130: 456–469. https://doi.org/10.1016/j.cell.2007.05.047

[131]

Yi Y, Du L, Qin M, et al., 2019, Regulation of atrial fibrosis by the bone. Hypertension, 73: 379–389. https://doi.org/10.1161/hypertensionaha.118.11544

[132]

Wang YL, Bai L, Shi XR, et al., 2022, Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction. J Mol Cell Cardiol, 167: 40–51. https://doi.org/10.1016/j.yjmcc.2022.03.003

[133]

Rico-Mesa JS, White A, Ahmadian-Tehrani A, et al., 2020, Mineralocorticoid receptor antagonists: A comprehensive review of finerenone. Curr Cardiol Rep, 22: 140. https://doi.org/10.1007/s11886-020-01399-7

[134]

Liu LC, Schutte E, Gansevoort RT, et al., 2015, Finerenone: Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs, 24: 1123–1135. https://doi.org/10.1517/13543784.2015.1059819

[135]

Kolkhof P, Borden SA, 2012, Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol, 350: 310–317. https://doi.org/10.1016/j.mce.2011.06.025

[136]

Pitt B, Zannad F, Remme WJ, et al., 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med, 341: 709–717. https://doi.org/10.1056/NEJM199909023411001

[137]

Agarwal R, Kolkhof P, Bakris G, et al., 2021, Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J, 42: 152–161. https://doi.org/10.1093/eurheartj/ehaa736

[138]

McMurray JJ, O’Meara E, 2004, Treatment of heart failure with spironolactone--trial and tribulations. N Engl J Med, 351: 526–528. https://doi.org/10.1056/nejmp048144

[139]

Ko DT, Juurlink DN, Mamdani MM, et al., 2006, Appropriateness of spironolactone prescribing in heart failure patients: A population-based study. J Card Fail, 12: 205–210. https://doi.org/10.1016/j.cardfail.2006.01.003

[140]

Wei L, Struthers AD, Fahey T, et al., 2010, Spironolactone use and renal toxicity: Population based longitudinal analysis. BMJ, 340: c1768. https://doi.org/10.1136/bmj.c1768

[141]

Vukadinovic D, Lavall D, Vukadinovic AN, et al., 2017, True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J, 188: 99–108. https://doi.org/10.1016/j.ahj.2017.03.011

[142]

Pitt B, Remme W, Zannad F, et al., 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 348: 1309–1321. https://doi.org/10.1056/nejmoa030207

[143]

Zannad F, McMurray JJ, Krum H, et al., 2011, Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 364: 11–21. https://doi.org/10.1056/NEJMoa1009492

[144]

Adamopoulos C, Ahmed A, Fay R, et al., 2009, Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: Insights from the ephesus trial. Eur J Heart Fail, 11: 1099–1105. https://doi.org/10.1093/eurjhf/hfp136

[145]

Montalescot G, Pitt B, Lopez de Sa E, et al., 2014, Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The randomized double-blind reminder study. Eur Heart J, 35: 2295–2302. https://doi.org/10.1093/eurheartj/ehu164

[146]

Filippatos G, Anker SD, Bohm M, et al., 2016, A randomized controlled study of finerenone vs. Eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J, 37: 2105–2114. https://doi.org/10.1093/eurheartj/ehw132

[147]

Bakris GL, Agarwal R, Anker SD, et al., 2020, Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N Engl J Med, 383: 2219–2229. https://doi.org/10.1056/NEJMoa2025845

[148]

Pitt B, Filippatos G, Agarwal R, et al., 2021, Cardiovascular events with finerenone in kidney disease and Type 2 diabetes. N Engl J Med, 385: 2252–2263. https://doi.org/10.1056/nejmoa2110956

[149]

Sueta D, Yamamoto E, Tsujita K, 2020, Mineralocorticoid receptor blockers: Novel selective nonsteroidal mineralocorticoid receptor antagonists. Curr Hypertens Rep, 22: 21. https://doi.org/10.1007/s11906-020-1023-y

[150]

Kintscher U, Bakris GL, Kolkhof P, 2022, Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol, 179: 3220–3234. https://doi.org/10.1111/bph.15747

Previous article in this issue

Next article in this issue

Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing